Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Egger, C; Muehlbacher, M; Schatz, M; Nickel, M.
Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.
J Clin Psychopharmacol. 2007; 27(5):475-478
Doi: 10.1097/jcp.0b013e31814b98e5
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Nickel-Palczynski Marius
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In a randomized controlled trial, we compared the efficacy of topiramate versus placebo in women undergoing olanzapine therapy and found that topiramate effectively contributed to weight loss in short-term treatment and had a positive effect on health-related quality of life, the patients' actual state of health, and psychological impairments. The aim of this observational study was to assess whether topiramate has a sustained benefit in long-term treatment of olanzapine-associated weight gain in subjects who had participated in the previous randomized controlled trial comparing topiramate with placebo. The subjects (topiramate group, n = 25; former placebo group, n = 18) were observed in an 18-month open-label study. After unblinding, subjects from the former topiramate group continued treatment with topiramate, whereas subjects from the former placebo group received neither placebo nor topiramate.The subjects were seen every 6 months, weighed, and tested with the SF-36 Health Survey, Scale of Well-Being, and the Adjective Checklist. According to the intent-to-treat principle, the repeated-measures analysis showed a significant interaction for the group-by-time effect for change of weight (P < 0.01) on the Scale of Well-Being (P < 0.01), all scales of the Adjective Checkist (all P < 0.01), and 5 scales (physical functioning, role limitations due to physical health, social functioning, mental health, and vitality) of the SF-36 Health Survey (all P < 0.01). Topiramate was well tolerated and seems to be effective and safe in the long-term treatment of olanzapine-related adiposity in women. Furthermore, positive changes in the patients' state of health, psychological impairments, and health-related quality of life could be also observed.
- Find related publications in this database (using NLM MeSH Indexing)
- Adiposity - drug effects
- Anti-Obesity Agents - adverse effects
- Antipsychotic Agents - adverse effects
- Benzodiazepines - adverse effects
- Female - adverse effects
- Follow-Up Studies - adverse effects
- Fructose - adverse effects
- Humans - adverse effects
- Quality of Life - adverse effects
- Weight Gain - drug effects
- Weight Loss - drug effects